Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | UBE2N | P61088 | 1/20 | 0.41 |
| ▸ | ELOVL6 | Q9H5J4 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7802259 | 0.91 | SMN1; SMN2 (0.45) | RAB9ANPC1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL7804372 | 0.89 | KMT2A (0.44) | RAB9ANPC1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL7795549 | 0.79 | MMP2 (0.51) | — | |
| SCHEMBL7795511 | 0.72 | CA12 (0.57) | — | |
| SCHEMBL7805690 | 0.71 | MMP2 (0.63) | — | |
| SCHEMBL7427121 | 0.70 | MEN1 (0.55) | RAB9AKMT2AMEN1SMN1; SMN2EPHX2 | |
| SCHEMBL7226664 | 0.67 | POLB (0.62) | RAB9ANPC1KMT2AMEN1UBE2N | |
| SCHEMBL25272718 | 0.64 | MMP2 (0.47) | KMT2AUBE2NALDH1A1 | |
| SCHEMBL7795572 | 0.64 | MMP1 (0.61) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL7805592 | 0.64 | MMP1 (0.50) | KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010056184-A1 | Pipecolinic acid derivatives, method of manufacturing the same and therapeutic agents containing these compounds | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2001-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056184-A1 | Pipecolinic acid derivatives, method of manufacturing the same and therapeutic agents containing these compounds | NCEH1, NOP10, HRH1 | RAB9A 149/4885NPC1 631/4885KMT2A 3353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.